Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 May;11(3):e1543. doi: 10.1002/wnan.1543. Epub 2018 Aug 2.

Abstract

The sequence-specific gene-silencing ability of small interfering RNA (siRNA) has been exploited as a new therapeutic approach for the treatment of a variety of diseases. However, efficient and safe delivery of siRNA into target cells is still a challenge in the clinical development of siRNA-based therapeutics. Recently, nucleic acid-based aptamers that target cell surface proteins have emerged as a new class of targeting moieties due to their high specificity and avidity. To date, various aptamer-mediated siRNA delivery systems have been developed to enhance the RNA interference (RNAi) efficacy of siRNA via targeted delivery. In this review, we summarize recent advances in developing aptamer-mediated siRNA delivery systems for RNAi therapeutics, mainly aptamer-siRNA chimeras and aptamer-functionalized nanocarriers incorporating siRNA, with a focus on their molecular designs and formulations. In addition, the challenges and engineering strategies of aptamer-mediated siRNA delivery systems for clinical translation are discussed. This article is categorized under: Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Keywords: RNA interference (RNAi); aptamer; aptamer-siRNA chimera; nanocarriers; siRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents
  • Aptamers, Nucleotide*
  • Cell Line, Tumor
  • Drug Delivery Systems*
  • Humans
  • Mice
  • Nanoparticles*
  • Neoplasms / drug therapy
  • RNA Interference
  • RNA, Small Interfering*

Substances

  • Antineoplastic Agents
  • Aptamers, Nucleotide
  • RNA, Small Interfering